Aerie Pharmaceuticals — Investor Presentation (March 2020)
26 slides from Aerie Pharmaceuticals's investor presentation, Mar 18, 2020
Slide 1: Company Overview Investor Presentation March 2020
Company Overview Investor Presentation March 2020 Exhibit 99.1
Slide 2: Important Information
For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified
Slide 3: Aerie Overview
Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are development stage product candidates and are no
Slide 4: Glaucoma Market Perspective
Glaucoma Market Perspective Sources: IQVIA: NPA Rx and NSP Unit data For Investor Use - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3X/Day Adjuncts 2019 U.S. Glaucoma Market Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agoni
Slide 5: Rocklatan Phase 3 Month 12 Responder Analysis
For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato
Slide 6: Topline Results from Rhopressa Phase 4 Multi-center Open-label Study (MOST)
Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv
Slide 7: U.S. Glaucoma Franchise Launch Update
For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 3/13/20 IQVIA Weekly
Slide 8: U.S. Glaucoma Franchise: TRx/NRx as of 3/6/20
U.S. Glaucoma Franchise: TRx/NRx as of 3/6/20 % TRx Change vs. Last Week % NRx Change vs. Last Week Rhopressa® 5.4% 2.2% Rocklatan® 7.4% 12.2% Franchise 6.0% 5.4% Market 4.9% 3.4% For Investor Use
Slide 9: TRx Growth By Branded Product
TRx Growth By Branded Product For Investor Use Product Dec ‘19 TRx Change from Dec ‘18 Aerie Franchise 45,798 24,506 Vyzulta® 13,796 5,752 Combigan® 159,299 2,877 Zioptan® 12,298 130 Lumigan® 201,668 137 Simbrinza® 42,666 (826) Cosopt PF® 5,268 (3,875) Alphagan® P 82,949 (4,365) Azopt® 43,486 (9,362
Slide 10: Market Access as of March 2020
For Investor Use Market Access as of March 2020 Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Commercial ~ 90% of covered lives Medicare Part D ~ 75% of covered lives Rocklatan® Commercial ~ 82% of covered lives Medicare Part D ~ 3
Slide 11: Active Engagement at Key Conferences
For Investor Use Active Engagement at Key Conferences February 2020: American Glaucoma Society (AGS) May 2020: Association of Research in Vision and Ophthalmology (ARVO) May 2020: American Society of Cataract and Refractive Surgeons (ASCRS) May/June 2020: European Glaucoma Society (EGS) July 2020: A
Slide 12: Expanding Aerie Franchise: Europe
For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i
Slide 13: Expanding Aerie Franchise: Japan
For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful top-line results released in November 2019 Phase 3 trials expected to be conducted in Japan Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2019. *TRx calculated from IQVIA unit data (1 month = 1 TRx) Aer
Slide 14: AR-13324-CS208 Japan Phase 2 Study Topline Results
AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim
Slide 15: Advancing the Pipeline
For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement
Slide 16: U.S. Dry Eye Market
For Investor Use U.S. Dry Eye Market Estimated 30 million dry eye sufferers in the United States Less than 3 million treated Sources: Mixture of public information, IQVIA , Market Scope and estimates – Feb 2020 US 2019 Sales: $1.6B est.
Slide 17: AVX-012 (now named AR-15512) for Dry Eye
For Investor Use AVX-012 (now named AR-15512) for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors TRPM8 receptor is a cold thermoreceptor involved in basal tear production (i.e.; sign) Modulation of TRPM8 also provides a cooling sensation upon instillation (i.e.; symptom) T
Slide 18: AR-15512 (TRPM8 Agonist) for Dry Eye
AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution
Slide 19: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights
AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Symptoms: SANDE Score Percentage of patients improving ≥20 score
Slide 20: Bringing Small Molecule Therapy to Back of the Eye
Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small molecules address a wider array of therapeutic
Slide 21: Aerie's Ophthalmic Implant Platform
For Investor Use Aerie’s Ophthalmic Implant Platform Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug candi
Slide 22: 2019 U.S. Retinal Disease Market
For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM
Slide 23: Aerie's Sustained Implant Opportunities
For Investor Use Aerie’s Sustained Implant Opportunities Markets in Need of Further Innovation: Retinal Vein Occlusion (RVO) Wet Age Related Macular Edema (wAMD) Diabetic Macular Edema (DME) Broadly Underserved Market Opportunities: Glaucoma Neuro-enhancement Dry AMD/Geographic Atrophy (GA)
Slide 24: Aerie's Lead Implant Product Candidates
For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout ~ H2 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administr
Slide 25: Aerie's Key Catalysts for 2020
Aerie’s Key Catalysts for 2020 Pipeline: Avizorex TRPM8 agonist for Dry Eye Phase 2/3 clinical study expected to commence H2 2020 AR-1105 Phase 2 RVO clinical study readout expected H2 2020 AR-13503 clinical study for Neuro-enhancement expected to commence H2 2020 Globalization: Roclanda® Mercury 3
Slide 26: Summary
For Investor Use Summary Key Priorities Successful commercialization in U.S. of Rhopressa® and Rocklatan® Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility – expected to be online H1 2020 Research Initiatives Avizorex TRPM8 agonist for dr
Aerie Pharmaceuticals — Investor Presentation (March 2020) on 6ix